0001425203-22-000009.txt : 20220414 0001425203-22-000009.hdr.sgml : 20220414 20220414142800 ACCESSION NUMBER: 0001425203-22-000009 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220228 FILED AS OF DATE: 20220414 DATE AS OF CHANGE: 20220414 EFFECTIVENESS DATE: 20220414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Instadose Pharma Corp. CENTRAL INDEX KEY: 0001697587 STANDARD INDUSTRIAL CLASSIFICATION: HOUSEHOLD FURNITURE [2510] IRS NUMBER: 813599639 STATE OF INCORPORATION: NV FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-216292 FILM NUMBER: 22826854 BUSINESS ADDRESS: STREET 1: 5500 NORTH SERVICE ROAD, SUITE 301 CITY: BURLINGTON STATE: A6 ZIP: L7L 6W6 BUSINESS PHONE: 800-542-8715 MAIL ADDRESS: STREET 1: 5500 NORTH SERVICE ROAD, SUITE 301 CITY: BURLINGTON STATE: A6 ZIP: L7L 6W6 FORMER COMPANY: FORMER CONFORMED NAME: Mikrocoze Inc. DATE OF NAME CHANGE: 20170208 NT 10-Q 1 instadose10qnt22822.htm INSTADOSE FORM 10-Q EXTENSION Converted by EDGARwiz

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SEC File Number 333-216292


FORM 12b-25


NOTIFICATION OF LATE FILING


(Check one): o Form 10-K   o Form 20-F  o Form 11-K  x Form 10-Q   o Form N-SAR


For Period Ended:  February 28, 2022

o      Transition Report on Form 10-K

o      Transition Report on Form 20-F

o      Transition Report on Form 11-K

o      Transition Report on Form 10-Q

o      Transition Report on Form N-SAR

For the Transition Period Ended: _______________

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.


If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

 


PART I  -  REGISTRANT INFORMATION

 

Full Name of Registrant

Instadose Pharma Corp.

Former Name if Applicable:


Address of Principal Executive Office (Street and Number):

5500 North Service Road, Suite 301,

City, State and Zip Code:

Burlington, Ontario, L7L 6W6.  


PART II  -  RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate) x



(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;



(b)

The subject annual report, semi-annual report, transition report on Forms 10-K, 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and



(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




PART III -  NARRATIVE


State below in reasonable detail the reasons why Forms 10-K, 11-K, 20-F, 10-Q, N-SAR, or the transition report portion thereof, could not be filed within the prescribed time period.

 

The disruptions in transportation, staffing, and technology systems which have occurred over the last six months to both the Company and the Company’s professional advisors along with the recent change in control have resulted in limited support from the Company’s staff and professional advisors. This has, in turn, delayed the Company’s ability to complete its financial statements and prepare the Report.


PART IV  -  OTHER INFORMATION

 

 

(1)

Name and telephone number of person to contact in regard to this notification:

 

J.M. Walker & Associates

Attorneys at Law


 

(303) 850-7637

(Name)


(Area Code) (Telephone number)

 



(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed?  If answer is no, identify report(s):  xYes oNo


(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof:  oYes  xNo



If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.


Instadose Pharma, Inc. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.


Date:

April 14, 2022

 

By:

/s/ Alex Wylie

 



 


 Alex Wylie

Chief Executive Officer